NCT02268032View on ClinicalTrials.gov

Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

July 15, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Healthy WomenInfertility, Female
Interventions
DRUG

DHEA

DHEA 2.2 g in vaginal ring

DRUG

Another Androgenic Agent (VRaA)

Testosterone 35 mg in vaginal ring

DRUG

Fixed combination of 2 androgenic agents (VR2A)

DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring

Trial Locations (1)

7501257

Mother and Health Research Institute (IDIMI), Faculty of Medicine, University of Chile, Santiago

Sponsors
All Listed Sponsors
lead

Laboratorios Andromaco S.A.

INDUSTRY

NCT02268032 - Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve | Biotech Hunter | Biotech Hunter